Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy
Epilepsy & Behavior · 2025
DOI: 10.1016/j.yebeh.2025.110670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Michele H Potashman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biohaven Pharmaceuticals, Inc., New Haven, CT, USA. Electronic address: michele.potashman@biohavenpharma.com. Hauptthemen laut MEDLINE: KCNQ2 Potassium Channel, Epilepsy, Developmental Disabilities. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biohaven Pharmaceuticals, Colorectal Cancer Alliance.
Abstract (Originalsprache)
BACKGROUND: KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) is a rare pediatric disorder characterized by seizures and neurodevelopmental impairments. Parent- and healthcare professional (HCP)-reported outcomes regarding the impacts of seizures and neurodevelopmental impairments may guide the design of clinically meaningful KCNQ2-DEE outcome measures. METHODS: Parents of children with KCNQ2-DEE (N = 53) and HCPs with KCNQ2-DEE expertise (N = 2) participated in qualitative interviews exploring signs, symptoms, and impacts of KCNQ2-DEE, and how varying KCNQ2-DEE phenotypes affect child development. Interviews were recorded, transcribed, coded, and analyzed by ATLAS.Ti v23 software. RESULTS: The most common KCNQ2-DEE concepts parents reported were difficulties with communication (88.9 %), and gross (81.5 %) and fine (63.0 %) motor problems. Difficulty with communication (74.1 %), behavioral disorders (37.0 %), and gross motor problems (24.1 %) were the most impactful and bothersome issues for parents. When asked to rate how impacted they were by each concept (0 = "not impacted" to 10 = "extremely impacted"), the most bothersome symptoms were difficulty with communication (mean score [SD] = 8.6 [1.7]; 87.0 % of parents), cognitive delays (8.1 [2.0]; 37.0 % parents), and personal care and hygiene issues (7.4 [2.2]; 29.6 % parents). Seizures were the least bothersome symptom post-infancy (mean score [SD] = 5.3 [3.6]; 87.0 % parents). Children's developmental abilities varied substantially within and between KCNQ2-DEE phenotypes and across age groups. Overall, HCPs reported largely similar concepts to parents of children with KCNQ2-DEE. CONCLUSIONS: These findings identify outcome domains important to those with KCNQ2-DEE and may inform the development of measurement tools and endpoint selection for therapeutic trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biohaven Pharmaceuticals, Inc., New Haven, CT, USA. Electronic address: michele.potashman@biohavenpharma.com.
- COA Science, Parexel International, London, UK.
- Patient-Centered Outcomes Assessments, Macclesfield, UK.
- Biohaven Pharmaceuticals, Inc., New Haven, CT, USA.
- Department of Neurology and Weill Institute for Neuroscience, University of California San Francisco, San Francisco, CA, USA.
- Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA.
Förderung
- Biohaven Pharmaceuticals
- Colorectal Cancer Alliance
Zitieren
APA
Potashman, M. H., Rudell, K., Abetz-Webb, L., Suminski, N., Gold, A., Doma, R., Jarodia, K., Buckley, C., Ridley, M., Lerner, J., Mather, J., Coric, V., Numis, A. L., Sands, T. T., Millichap, J., Berg, A. T., & L'Italien, G. (2025). Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110670
Vancouver
Potashman MH, Rudell K, Abetz-Webb L, Suminski N, Gold A, Doma R, et al. Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110670
BibTeX
@article{Potashman2025,
author = {Potashman, Michele H and Rudell, Katja and Abetz-Webb, Linda and Suminski, Naomi and Gold, Audra and Doma, Rinchen and Jarodia, Kavita and Buckley, Chris and Ridley, Matthew and Lerner, Jason and Mather, Jim and Coric, Vlad and Numis, Adam L and Sands, Tristan T and Millichap, John and Berg, Anne T and L'Italien, Gil},
title = {Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy},
journal = {Epilepsy & Behavior},
year = {2025},
doi = {10.1016/j.yebeh.2025.110670}
}
EUVIMED